This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT06055192
Recruitment Status : Not yet recruiting
First Posted : September 26, 2023
Last Update Posted : September 26, 2023
Opera CRO, a TIGERMED Group Company
Information provided by (Responsible Party):
Effik SA

Brief Summary:
The latest data on the prevalence of nausea in pregnancy in Switzerland is dated 2015 but has been hypothesised that the recent introduction on the market of new drugs against this symptom could modify its epidemiology. For this reason, we have planned the present survey, calculating an adequate sample size of Swiss pregnant women (the population of interest) and, according to a cross-sectional design, planning the collection of response variables with the aim of estimating the prevalence of burden and nausea and vomiting in pregnancy

Condition or disease Intervention/treatment
Nausea Vomiting of Pregnancy Other: Survey

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Other
Time Perspective: Other
Official Title: Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
Estimated Study Start Date : September 2023
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : October 2024

Resource links provided by the National Library of Medicine

Intervention Details:
  • Other: Survey

Primary Outcome Measures :
  1. Primary Outcome Measure [ Time Frame: 185 days ]
    Evaluate the prevalence and burden that the symptoms of nausea and vomiting have in pregnant women in Switzerland

Secondary Outcome Measures :
  1. Secondary Outcome Measure [ Time Frame: 185 days ]
    demographic data (including ethnicity: Caucasian, African, Asian or Other).

  2. Secondary Outcome Measure [ Time Frame: 185 days ]
    NVP prevalence

  3. Secondary Outcome Measure [ Time Frame: 185 days ]
    Percentage of mild, medium, and severe cases based on PUQE-24.

  4. Secondary Outcome Measure [ Time Frame: 185 days ]
    Percentage of answer allocation to NVP related questions

  5. Secondary Outcome Measure [ Time Frame: 185 days ]
    Onset for each symptom and its duration

  6. Secondary Outcome Measure [ Time Frame: 185 days ]
    Correlations between demographic data (age, first pregnancy status, multiparity, geographical origin, kinds of work and educational qualification) and the presence of symptoms and their severity.

  7. Secondary Outcome Measure [ Time Frame: 185 days ]
    Correlation of the above-mentioned parameters with the use of non-pharmacological, pharmacological (e.g., Cariban®) or both therapies.

  8. Secondary Outcome Measure [ Time Frame: 185 days ]
    Analysis of drug therapies, their correlation with the severity of the symptoms during pregnancy and with the possible outcomes of the same

  9. Secondary Outcome Measure [ Time Frame: 185 days ]
    Correlation between the severity of the symptoms and the consequences on the woman's personal life (family, work, etc.).

  10. Secondary Outcome Measure [ Time Frame: 185 days ]
    Number of cases with hospitalization in relation to total and severity of symptoms (PUQE-24).

  11. Secondary Outcome Measure [ Time Frame: 185 days ]
    Correlation between symptoms in pregnancy and outcomes based on data from the post pregnancy questionnaire (weight of the new-born, gestational age at birth and any complications).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   200 women during the weeks 18-22 of their pregnancy
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
200 women during the weeks 18-22 of their pregnancy

Inclusion Criteria:

Subjects will be eligible for inclusion if all the following criteria are respected:

  • Women aged ≥ 18 years.
  • Women in physiological pregnancy and between the 18th and 22nd week of pregnancy (at time of morphological ultrasound).
  • Women able to communicate adequately with the Investigator and able to read, understand and provide the answers required by the questionnaires in one of the languages in which they will be provided (Italian, German, French or English).
  • Women able to understand and who can provide valid informed consent to the Survey.

Exclusion Criteria:

  • Subjects fulfilling one or more of the following exclusion criteria will not be included in the study:

    • Twin pregnancy.
    • Medically assisted procreation (MAP).
SR 810.301 - Ordinance of 20 September 2013 on Human Research with the Exception of Clinical Trials (Human Research Ordinance, HRO) [Internet]. [cited 2022 Jun 13]. Available from:
fedlex-data-admin-ch-eli-cc-2013-643-20140101-en-pdf-a.pdf [Internet]. [cited 2022 Jun 13]. Available from:
WMA - The World Medical Association-WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects [Internet]. [cited 2022 Jun 13]. Available from:
de Tejada BM, Vonzun L, Mandach DUV, Burch A, Yaron M, Hodel M, et al. Nausea and Vomiting of Pregnancy, Hyperemesis gravidarum. :5.
Brott NR, Reddivari AKR. Doxylamine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 22]. Available from:
APGO. APGO. Nausea and vomiting of pregnancy. APGO Educational series on women's health issues. Boston: Jespersen & Associates, LLC; 2013. 2013.
Nausea and Vomiting of Pregnancy (NVP). 2022;
Office FS. Births [Internet]. [cited 2022 Jun 14]. Available from:

Layout table for additonal information
Responsible Party: Effik SA Identifier: NCT06055192    
Other Study ID Numbers: OPEFF/0122/SU
First Posted: September 26, 2023    Key Record Dates
Last Update Posted: September 26, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Effik SA:
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive